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Abstract
Purpose—Compare the post-surgery red cell mass as indicated by hematocrit value of
orthognathic surgery patients given iron supplementation and a single presurgery dose of
erythropoietin alpha(EPO) and patients who did not receive either EPO or iron supplementation
(NEPO).
Subjects and Methods—Subjects who had a Lefort I osteotomy(LFI) or a combination of a
LFI and bilateral sagittal split osteotomy(BSSO) between 2005 and 2008, and were at least 13
years of age, were included. Subjects were excluded if they had a history of maxillofacial trauma,
a craniofacial syndrome, or a major systemic medical condition. Subjects had either the drug
administered with iron supplements prior to surgery(EPO; Surgeon A protocol) or received neither
(NEPO; Surgeon B protocol). Venous blood samples were taken, in accordance with clinic
protocol, before surgery (before administration of EPO) and on post-surgery day 1. Multiple linear
regression with backward selection was used to analyze the change in hematocrit value.
Explanatory variables included group, pre-surgery hematocrit, age, gender, length of surgery,
blood loss, and crystalloid (fluid replacement) volume.
Results—178 eligible patients were included: 86 patients (48%) had a combination LFI and
BSSO and 92 patients (52%) an isolated LFI. 114 (64%) had erythropoietin alpha/ iron
supplements administered presurgery, while 64 did not. The average change in hematocrit as an
indicator of the change in red cell mass was statistically significantly different(P= 0.01) for the
subjects who received preoperative administration of EPO with iron supplementation compared to
© 2012 The American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
Corresponding Author: Dr. Ceib, Phillips 919-966-2764, FAX 919-843-8864, ceib_phillips@dentistry.unc.edu.
*School of Dentistry, University of North Carolina, Chapel Hill, NC 27599-7450
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
J Oral Maxillofac Surg. Author manuscript; available in PMC 2013 November 01.
Published in final edited form as:













those who did not receive EPO+Iron. The administration of EPO + iron was protective: the
decrease in hematocrit after surgery was smaller for subjects in the EPO group even after
controlling for age, gender, preoperative hematocrit, length of surgery, blood loss, and crystalloid
(fluid replacement ) volume.
Conclusions—A single presurgery dose of erythropoietin with iron supplementation resulted in
a smaller decrease, on average, in post-surgery red cell mass as indicated by hematocrit value in
patients with complicated orthognathic surgery procedures.
Introduction
Improvements in orthognathic surgical techniques over time, including a shorter operating
time, use of hypotensive anesthesia, local anesthetics with vasoconstriction, blood salvaging
methods, and careful management of blood coagulation, have reduced the blood loss that
occurs during these procedures. A recent systematic review reported that the blood loss
observed in patients during surgery, LeFort I or mandibular ramus osteotomies or both
combined, was less than the usual limits set for blood transfusion.1 However, even if a blood
transfusion is not required according to more global guidelines for major surgery,
perioperative consequences related to blood loss can result in decreased hemoglobin
molecules available to oxygenate tissue. Consequences can potentially affect recovery even
in usually healthy patients having orthognathic surgery. These consequences may include
decreased endurance and a longer post-surgery healing period.2–4
Presurgery administration of erythropoietin alpha may be beneficial by increasing the red
cell mass prior to surgery thereby preventing or reducing the reduction in red cell mass that
occurs as a result of blood loss during the surgery.5–7 Baseline hematological parameters for
patients who received EPO before a total knee arthroplasty were not significantly different
from those who had preoperative autologous blood donation, but the EPO group, on
average, had significantly higher hemoglobin, hematocrit, and reticulocyte count by the day
of surgery, and this difference remained for 1 to 2 days postoperatively.5,7 These finding
were also reported in a randomized trial of colorectal cancer patients having surgery.6
Erythropoietin is a glycoproteinic hormone naturally produced by renal cortical interstitial
cells. When production is stimulated by tissue hypoxia, erythropoietin interacts with
erythrocytes in the bone marrow to increase red blood cell production. The action of
erythropoietin alpha is identical to the naturally occurring erythropoietin and the presurgery
administration bypasses the physiological mechanisms required for stimulation of
production by the kidney.8
The presurgery combination of Erythropoietin Alpha, given intravenously or
subcutaneously, and oral iron supplementation has been used in orthopedic surgery since the
1990s. The use of erythropoietin alpha in major surgical procedures has been shown to
decrease the frequency of transfusion, at surgery and in the immediate post-surgery
period.9–12 These outcomes were beneficial to patients even when the patients had an
adequate red cell mass at surgery and did not require a transfusion by usual guidelines.13 In
a randomized trial of patients undergoing primary total joint arthroplasty, patients who
received EPO had significantly higher vigor after surgery and required fewer transfusions
than those patients who received a preoperative autologous donation.9 Time to ambulation
and time to discharge were significantly longer in patients who had transfusion while
undergoing orthopaedic surgery compared to those who received EPO.10
The purpose of this retrospective study was to compare the change in red cell mass as
indicated by the change in hematocrit values from pre- to post-surgery of orthognathic
surgery patients who were given Trinsicon iron supplementation and a single presurgery
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injection of erythropoietin alpha(EPO) and patients who did not receive either EPO or iron
supplementation.
Materials and Methods
The medical records of subjects previously enrolled in a study on the stability of
orthognathic surgery procedures were reviewed for this retrospective assessment of the
effects of EPO. The project was approved by the Biomedical Institutional Review Board.
Subjects who had a Lefort I osteotomy (LFI) or a combination of a LFI and bilateral sagittal
split osteotomy(BSSO) to correct a developmental dentofacial disharmony between 2005
and 2008, were at least 13 years of age, and healthy (ASA I or II) were eligible. Subjects
were excluded if they had a history of maxillofacial trauma, a craniofacial syndrome, or a
major systemic medical condition. Data from the medical records of 179 patients were
included: 86 patients (48%) had a combination LFI and BSSO and 92 patients (52%) an
isolated LFI. No patients received autologous blood pre or post-surgery. During the time
frame of this study, only 1 patient received a homologous blood transfusion immediately
post-surgery. This patient was excluded from the analysis.
Subjects either had the drug administered with iron supplements prior to surgery (EPO;
Surgeon A protocol) or did not receive EPO or iron supplements (NEPO; Surgeon B
protocol). Patients in the EPO group were prescribed a one month supply of Trinsicon (Iron,
Vitamin C, Intrinsic factor, B12-UCB Inc, Rochester, NY) with instructions to take the
supplement for two weeks prior to surgery and for two weeks after surgery. These same
patients received a single subcutaneous injection of erythropoietin alpha (40,000U)
approximately 1 week prior to surgery. The NEPO group was not given a subcutaneous
injection of EPO or Trinsicon supplements.
All surgical procedures for the patients were performed in a similar manner. Each surgical
team consisted of one faculty and one senior resident member. All of the surgeries were
performed with hypotensive anesthesia, defined by a systolic blood pressure (SBP) of 90mm
Hg. or less, maintained during the key points of the procedure in order to minimize blood
loss. Specifically, hypotensive anesthesia was maintained at the time of maxillary down-
fracture and continued through, at a minimum, the repositioning and fixation of the maxilla.
All presurgery blood samples were obtained at the presurgery workup appointment, but
because of the timing of the clinical protocol for presurgery workups, the venous blood
sample was obtained prior to the EPO injection. Blood loss at surgery was estimated by
consensus between the anesthesiologist and the circulating operating room nurse using the
contents of the suction bottle and the sponge count. The volume of fluid replacement
(crystalloid) was obtained from the operative notes. The post-surgery venous sample was
obtained on post-surgery day 1 prior to discharge. Hematocrit values (g/dL), the percentage
of packed red blood cells in a sample of venous blood as a measure of red cell mass, were
assessed at both visits and the difference between the pre- and post-surgery values (loss) was
calculated.
Bivariate analyses were used to compare the characteristics and outcomes of the EPO and
NEPO groups: chi-square analysis for nominal variables (type of procedure, gender, and
ethnicity) and Wilcoxon rank sum test for age, length of surgery, blood loss, and fluid
replacement. A linear regression model with backward selection was used to analyze the
change in hematocrit. Potential explanatory variables were group (EPO vs NEPO), age at
surgery, gender, preoperative hematocrit, length of surgery, blood loss, and crystalloid (fluid
replacement) volume. Continuous explanatory measures were centered (value - mean ) prior
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to analysis. Reference groups were EPO and male. All of the analyses were conducted using
SAS (version 9.2).
Results
Approximately two-thirds of the 178 subjects were female and, on average, 21 years of age
(Table 1). Forty-eight percent of the subjects had both a BSSO and LF1. As expected,
average length of surgery, estimated blood loss, and fluid replacement were higher for
patients having LFI and BSSO as compared to LFI only (Table 1).
114 patients (64%) had erythropoietin alpha/ iron supplements administered presurgery,
while 64 patients did not (Table 1). The proportion of subjects in the EPO and the NEPO
groups did not differ with respect to the distribution of gender or ethnicity (Table 1).
Average presurgery hematocrit, age at surgery, length of surgery, estimated blood loss and
fluid replacement volume were not significantly different between the EPO and NEPO
patients (Table 1 and 2). However, the proportion of those who had LFI only was
significantly different between the two groups, P<0.01 (Table 2). A higher percentage of
subjects in the NEPO group had LFI only, 70%, as compared to the EPO group, 41%. For
subjects having LFI only, the pre to post-surgery decrease in the mean hematocrit was 4.7g/
dL for the EPO subjects and 5.4 for the NEPO subjects. Similarly, for subjects having LFI
and BSSO the pre to post-surgery hematocrit differential was 8.2 g/dL for the EPO subjects
and 10.2 for the NEPO subjects. As expected, the change in hematocrit was inversely related
to length of surgery (r=−.50; P<0.0001), estimated blood loss (r = −.48; P<0.0001), and
volume of crystalloid IV fluid received (r=−.62; P<0.0001) ie longer surgery times, greater
blood loss, and greater volume of fluid received were associated with greater decrease in
hematocrit from pre to post-surgery.
Age at surgery was not significantly related to the change in hematocrit after controlling for
the other covariates (P>0.05). Each of the other explanatory variables were significantly
related to the change in hematocrit even after adjustment for the other explanatory variables
(Table 3). For example, the loss in hematocrit would be 0.56 g/dL greater for every 100 unit
increase in blood loss above the average loss. The average change in hematocrit was
statistically significantly different (P = 0.01) between the EPO and NEPO groups even after
adjusting for pre-surgery hematocrit, sex, length of surgery, estimated blood loss, and fluid
replacement volume (Table 3). The administration of EPO with iron supplementation was a
protective factor. On average, subjects in the EPO group lost 1.37 g/dL less than those in the
NEPO group after adjusting for the other covariates. Being male was also protective in that
males tended, on average, to experience less of a decrease in hematocrit than females
(Figure 1).
Discussion
Presurgery administration of Erythropoietin Alpha with iron supplementation in patients
having LFI or LFI and BSSO was associated with a statistically significant differential in the
reduction in red cell mass pre to post-surgery as measured by hematocrit assessed from
venous blood samples. These results demonstrate a statistically significant benefit in using
EPO with iron supplementation. We hypothesize that this benefit reflects a maintenance or
increase of hematocrit, used in this study as a surrogate for red cell mass, prior to
orthognathic surgery as compared to no EPO or iron supplementation. The outcome was
achieved with a singlepresurgery dose of EPO. The differential between the EPO and NEPO
groups with respect to the loss in hematocrit from before to after surgery was greater for
those patients who had LFI and BSSO than for those who had a LFI only: the decrease for
patients with 2 jaw surgery in the NEPO group was 2 g/dL greater than in the EPO group
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versus 0.7 greater decrease for the LFI only patients in the NEPO group. This suggests that
patients that require a more involved and longer orthognathic surgical procedure may benefit
more from the administration of EPO than those having a procedure limited to the maxilla.
In most instances surgeons can estimate the complexity and the length of a planned surgery
during the planning stages and include presurgery EPO when it might be beneficial,
particularly to avoid homologous blood transfusion.
In orthopedic surgery, multiple presurgery dosing is common. For example, Feagan et al
reported that patients responded best if red cell mass was increased to a higher level before
or just after surgery. This was achieved giving 600 IU/kg (~40000U) erythropoietin every
week, starting 4 weeks prior to surgery (Days -21, -14, -7, 0)or 300 IU/kg (~20000U)
erythropoietin administered daily for 15 days (10 days presurgery and 5 days post-
surgery).11 Either of these two methods combined with daily iron supplementation of at least
200mg/day when receiving erythropoietin were successful in reducing the frequency of
transfusion. It should be noted, however, that the blood loss expected with hip replacement
surgery exceeds that expected with orthognathic surgery, even with two jaw osteotomies.
Although EPO administration is common practice in major orthopedic surgery, this is the
first report on the positive effect on hematocrit of EPO administration as a single presurgery
dose in orthognathic surgery patients. The benefit, moreover, occurred in healthy,
predominately young adults, who prior to surgery had hematocrit values in the normal range.
Autologous blood transfusion has been used effectively to avoid homologous blood use in
orthognathic surgery patients at our center for two decades. Subjects were transfused with
their own blood only when they were sufficiently awake in the recovery room to identify
their signature on the blood storage bag. This procedure minimized the danger of receiving
the wrong blood; no orthognathic surgery patients received the wrong autologous blood
while this procedure was employed. The use of EPO and iron supplementation was initiated
when autologous blood donation with elective surgery was discouraged at our academic
center because of the complexity of the administration and the expense use ratio of the
required protocols in parallel with protocols for homologous blood. Pola et al have
enumerated the possible unwanted clinical side-effects of autologous blood donation and
transfusion in addition to the administrative complexity. 14
Our study has limitations even for patients having orthognathic surgery. The subjects were
young and healthy. The same degree of benefit may not accrue to older patients or those
with a chronic systemic disease. Only clinical outcomes were measured. It is possible that
quality of life outcomes such as the return to a usual lifestyle or sports and recreation may be
the most important benefit of maintaining a red cell mass close to presurgery values,
particularly for active young adults. The study was not randomized; all the data were
gathered retrospectively. Although the surgery protocols and the conduct of the surgery
itself are similar at UNC no matter who the attending faculty surgeon is, the subjects were
not randomized to surgery team or to administration of EPO. The data on blood loss were
estimated in the operating room reasonably accurately, but no data were collected on blood
loss in the hours following surgery. In addition, hematocrit offers a reasonable estimate of a
patient’s red cell mass but values in the post-surgery period are affected by the status of a
patient’s hydration. The regimen for fluid administration in the operating and recovery room
was similar for all UNC patients, but the results were not controlled for the volume and type
of IV fluids or colloid administered. Data also were not controlled for body mass index, a
variable that could also affect both clinical and quality of life outcomes. However, the data
we report has the potential to be beneficial to patients having complex jaw surgery. This
study should be followed by a prospective, randomized trial of EPO with iron
supplementation in patients who are having LFI/BSSO surgery. Further studies might
suggest a benefit to patients from EPO administration with other maxillofacial surgery
Politano et al. Page 5













procedures. Both clinical and quality of life outcomesin the post-surgery period should be
assessed.
How might clinicians interpret and apply our findings at this time? Our data indicate the
efficacy of a single dose administration of EPO with iron supplementation. If a complicated
and lengthy orthognathic surgery is anticipated, this schedule of EPO administration should
be considered as an alternative to homologous or autologous blood administration or no
replacement of red cell mass.
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Estimated Loss in Hematocrit by Gender and EPO Group at the Average Values for
Preoperative Hematocrit, Length of Surgery, Blood Loss and Fluid Replacement
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Table 3
Effect of Explanatory Factors on the loss in hematocrit (g/dL) from before surgery to iafter surgery.
Variable Estimate SE F Value P value
Intercept 8.27 0.44 352.6 <.0001
Preoperative Hematocrit 0.40 0.08 22.09 <.0001
Gender (Male) −1.37 0.49 7.84 0.006
Group (EPO) −1.59 0.61 6.86 0.01
Length of Surgery 0.83 0.24 12.28 0.001
Blood Loss 0.005 0.002 9.47 0.003
Crystalloid 0.0008 0.0003 8.59 0.004
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